Defymed
Séverine Sigrist founded Defymed in 2011 and has since participated in the growth and international expansion of the company. With more than 20 years of scientific and management experience, Séverine puts her expertise at the service of Defymed’s development. She has launched many projects dealing with type 1 and type 2 diabetes: survival of pancreatic islets after isolation, oral insulin therapy, macro-encapsulation of insulin-secreting cells, etc.